MAR 31, 2020 6:28 AM PDT

Ovarian cancer metastasis and CPT1A

Research published in the journal Molecular Cancer Research from collaborators at the University of Colorado Cancer Center hits on new insight as to how ovarian cancer spreads. While ovarian cancer grows in the fallopian tubes, in order to spread it must depend on an energy source. The researchers have discovered that ovarian cancer cells rely on cells with high-fat content to garner the energy to metastasize and that a specific enzyme CPT1A allows them to do so. This discovery provides an opportunity to target CPT1A in order to slow the spread of ovarian cancer cells, a realization that could open new paths for future treatment options.

Benjamin Bitler, Ph.D., from the CU Cancer Center, explains that he and his colleagues observed how the enzyme CPT1A controls how much fat ovarian cancer cells can burn. From there, they hypothesized that limiting cells' access to CPT1A could cut off the energy supply they need to spread.

Referring to ovarian cancer cells, Bitler says, "When they break off, they metabolically shift to use fats more - it allows these cells to survive and then they seek out or are able to colonize fatty tissue. It looked like CPT1A was the rate-limiting step in their ability to do this," says Bitler, who is also an assistant professor in the CU School of Medicine Department of Obstetrics & Gynecology.

Bitler worked with colleague Isabel Schlaepfer, Ph.D. to further understand the role of CPT1A. Together, they showed that the presence of the enzyme prevented ovarian cancer cells from dying, while the lack of the enzyme significantly reduced the spread of human cancer cells grown in mouse models. "It didn't completely abolish ovarian cancer cells' capacity to go to fat-rich sites, but it reduced it pretty dramatically," says Bitler.

The researchers are working to move this discovery out of the laboratory and into clinical trials. "There's a drug called etomoxir that inhibits CPT1A and has been tested as a preventative for congestive heart failure," Bitler says. "Our hope is that we could use etomoxir to treat chemo-resistant disease," Bitler says.

Sources: Molecular Cancer Research, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
NOV 02, 2020
Cancer
Age impacts response to melanoma treatment
NOV 02, 2020
Age impacts response to melanoma treatment
Research from the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Bloomberg School of Public Health& ...
NOV 24, 2020
Cancer
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
NOV 24, 2020
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
Did you know sleeping is great? Apparently, getting a full eight hours every night can make you look fabulous and solve ...
DEC 02, 2020
Cancer
Investigating the Active Components of an Herbal Mushroom
DEC 02, 2020
Investigating the Active Components of an Herbal Mushroom
When people think of traditional medicine, often what comes to mind are the old herbal medical practices in Asian countr ...
DEC 08, 2020
Immunology
Drug Targets Cold Tumors' Achilles Heel
DEC 08, 2020
Drug Targets Cold Tumors' Achilles Heel
Immunotherapies have emerged as a powerful treatment modality for cancer. They join chemotherapy, surgery, radiotherapy, ...
DEC 20, 2020
Cell & Molecular Biology
Chromatin Doesn't Behave Like a Liquid or Solid - It's a Gel
DEC 20, 2020
Chromatin Doesn't Behave Like a Liquid or Solid - It's a Gel
A cell's nucleus has to hold the entire genome. To do that, the DNA has to be carefully arranged and compacted by protei ...
DEC 27, 2020
Immunology
A Fatty Diet can be Fuel for Tumor Growth!
DEC 27, 2020
A Fatty Diet can be Fuel for Tumor Growth!
Obesity is a significant problem in our societies with increasing the risk for many diseases, including cancer. Can ...
Loading Comments...